Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

Autor: Karin Ribi, Beat Thürlimann, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philippe von Burg, Meinrad Mannhart, Clemens B. Caspar, Roger von Moos, Michael Mark

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)

Abstract Background Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (Qo

Externí odkaz: https://doaj.org/article/2f4e37bedf8d49deba6179a01a81e7f8

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)

Autor: Michael Mark, Beat Thürlimann, Karin Ribi, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philipp von Burg, Meinrad Mannhart, Clemens B Caspar, Roger von Moos

Publikováno v: Journal of Bone Oncology, Vol 21, Iss , Pp - (2020)

Background: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors, but knowledge of their routine care use and the therapeutic implications remains limited. This non-interventional study aime

Externí odkaz: https://doaj.org/article/0e77d4190fbb434184b3402e30ef62de

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study

Autor: Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler, Roger von Moos

Publikováno v: Cancers; Volume 14; Issue 14; Pages: 3522

Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc34bfdb912f66668753a513a701166
https://pubmed.ncbi.nlm.nih.gov/35884583

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study

Autor: Sandro Anchisi, Vera Bühler, Daniel Betticher, Stefanie Pederiva, Roger von Moos, Regina Woelky, Miklos Pless, Marco Dressler, Sacha I. Rothschild, Peter Moosmann, Reinhard Zenhäusern, R. A. Popescu, Markus Borner, Daniel Rauch, Claudia Papet, Antonello Calderoni

Publikováno v: Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x
Cancer Chemotherapy and Pharmacology

PURPOSE The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60ebb5f531dd173e90b577ae1e4b90e6
https://doi.org/10.1007/s00280-019-03927-x

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study

Autor: Anita Feller, Michael Mark, Corinne Schär, Thomas von Briel, Matthias Schwenkglenks, Beat Thürlimann, Roger von Moos, Ursina Zürrer-Härdi, Sandro Tiziano Stoffel, Daniel Dietrich, Richard Cathomas, Sandro Anchisi, Judith E Lupatsch, Silke Gillessen

Publikováno v: Swiss medical weekly. 151

BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone metastase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3357b2180d4fb90065a0262dd0c79185
https://pubmed.ncbi.nlm.nih.gov/33705559